Skip to Content

PGIM Jennison Health Sciences Z PHSZX

Analyst rating as of
NAV / 1-Day Return
39.65  /  0.41 %
Total Assets
1.7 Bil
Adj. Expense Ratio
0.840%
Expense Ratio
0.840%
Fee Level
Below Average
Longest Manager Tenure
23.00 years
Category
Health
Investment Style
Large Growth
Min. Initial Investment
0
Status
Open
TTM Yield
0.00%
Turnover
77%

Morningstar’s Analysis

Will PHSZX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

PGIM Jennison Health Sciences' Longtime Manager to Retire in June 2022; Ratings Unchanged

Analyst Note

| |

David Chan, a veteran of subadvisor Jennison Associates and lead manager of PGIM Jennison Health Sciences since the fund's 1999 inception, will step down and retire from the firm at the end of June 2022. Given the depth and experience of Jennison's healthcare team, Chan's departure is not detrimental to the strategy. It remains under the watch of industry veterans Debra Netschert and Daniel Matviyenko, who have comanaged the strategy since 2015 and 2020, respectively. With some continuity in the management ranks and no anticipated changes to the well-established approach, the strategy's Morningstar Analyst Ratings are unchanged.

Unlock our full analysis with Morningstar Investor